Aligos Therapeutics, Inc.
ALGS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $1 |
| % Growth | -23.2% | 210.3% | -50.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $0 | $1 |
| % Margin | 100% | 73.2% | 100% | 100% |
| R&D Expenses | $24 | $14 | $15 | $16 |
| G&A Expenses | $5 | $6 | $5 | $5 |
| SG&A Expenses | $5 | $6 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $29 | $19 | $20 | $21 |
| Operating Income | -$28 | -$19 | -$19 | -$21 |
| % Margin | -3,827.4% | -1,924% | -6,187.5% | -3,269.2% |
| Other Income/Exp. Net | -$3 | $3 | $62 | -$62 |
| Pre-Tax Income | -$31 | -$16 | $43 | -$82 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32 | -$16 | $43 | -$82 |
| % Margin | -4,256% | -1,643.8% | 13,854.7% | -13,060.4% |
| EPS | -3.04 | -1.53 | 5.12 | -13.08 |
| % Growth | -98.7% | -129.9% | 139.1% | – |
| EPS Diluted | -3.04 | -1.53 | -2.11 | -13.08 |
| Weighted Avg Shares Out | 10 | 10 | 8 | 6 |
| Weighted Avg Shares Out Dil | 10 | 10 | 9 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $1 | $1 |
| EBITDA | -$31 | -$15 | -$19 | -$20 |
| % Margin | -4,154.3% | -1,597.8% | -6,023.5% | -3,162.5% |